Journal
TRENDS IN MOLECULAR MEDICINE
Volume 25, Issue 11, Pages 993-1009Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2019.05.007
Keywords
-
Funding
- Breast Cancer Now [2014NovPR352]
- Cancer Research UK (CRUK) [C52376/A25500]
- Neil and Hilary Murphy via Circles of Influences (University of Birmingham)
- University of Birmingham
- MRC [MR/M009912/1] Funding Source: UKRI
Ask authors/readers for more resources
Post-translational modification (PTM) of proteins is vital for increasing proteome diversity and maintaining cellular homeostasis. If the writing, reading, and removal of modifications are not controlled, cancer can develop. Arginine methylation is an understudied modification that is increasingly associated with cancer progression. Consequently protein arginine methyltransferases (PRMTs), the writers of arginine methylation, have rapidly gained interest as novel drug targets. However, for clinical success a deep mechanistic understanding of the biology of PRMTs is required. In this review we focus on advances made regarding the role of PRMTs in stem cell biology, epigenetics, splicing, immune surveillance and the DNA damage response, and highlight the rapid rise of specific inhibitors that are now in clinical trials for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available